STOCK TITAN

Ocugen to Present at Investing in Cures Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri will be a panelist at the Investing in Cures Summit 2024 to discuss therapeutic approaches for retinal diseases. The event will focus on gene agnostic strategies to address retinal disease.
Positive
  • None.
Negative
  • None.

MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ.

“I look forward to joining my peers in discussing therapeutic approaches to treat inherited retinal diseases that can help slow or reverse degeneration regardless of the underlying genetic cause,” said Dr. Musunuri. “Ocugen’s modifier gene therapy platform can potentially address multiple genetic defects with a single product utilizing a gene agnostic approach that restores homeostasis in the retina.”

The Investing in Cures Summit includes presentations by the world’s leading industry, clinical and retinal science innovators and is hosted by the Foundation Fighting Blindness and the RD Fund.

Details for the panel are as follows:

Event: Investing in Cures Summit 2024—Global Community

Topic: Gene Agnostics: Broad Spectrum Therapeutic Strategies to Address Retinal Disease

Time: 2:45-3:20 p.m. MT

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com


FAQ

What event is Dr. Shankar Musunuri participating in?

Dr. Shankar Musunuri will be a panelist at the Investing in Cures Summit 2024.

What is the main topic of the Investing in Cures Summit 2024?

The main topic is Gene Agnostics: Broad Spectrum Therapeutic Strategies to Address Retinal Disease.

When and where will the Investing in Cures Summit 2024 take place?

The summit will be held from March 8-9, 2024, at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ.

Who is hosting the Investing in Cures Summit 2024?

The summit is hosted by the Foundation Fighting Blindness and the RD Fund.

What is Ocugen's modifier gene therapy platform focused on?

Ocugen's modifier gene therapy platform aims to address multiple genetic defects with a single product using a gene agnostic approach to restore homeostasis in the retina.

Ocugen, Inc.

NASDAQ:OCGN

OCGN Rankings

OCGN Latest News

OCGN Stock Data

450.32M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
United States of America
MALVERN

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.